Pharmaceutical

MaxCyte and Kamau Therapeutics sign platform license agreement

MaxCyte has entered into a license agreement with Kamau Therapeutics, a clinical-stage company focused on stem cell therapy gene correction.

Sep 18, 2024 - 04:00
MaxCyte and Kamau Therapeutics sign platform license agreement
MaxCyte has entered into a license agreement with Kamau Therapeutics, a clinical-stage company focused on stem cell therapy gene correction.
Read the original article

Tags:

Previous Article

FDA grants RMAT to Poseida’s CAR-T cell therapy P-BCMA-ALLO1

Next Article

Sanofi begins shipping BEYFORTUS to US for RSV prevention in infants

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Risk adjusted net present value: What is the current va...

Dec 15, 2024

STAT+: J&J agrees not to enforce patents on a key tuberculosis drug in dozens of poor countries

STAT+: J&J agrees not to enforce patents on a key tuber...

Sep 30, 2023

STAT+: FDA cracks down on websites that claim to sell chemicals in obesity drugs Wegovy, Zepbound

STAT+: FDA cracks down on websites that claim to sell c...

Feb 15, 2024